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Abstract
Objectives: Hypertension and diabetes are common in rapidly urbanising sub-Saharan African communities. 
However, lack of longitudinal data in these regions prevents adequate analysis of the link between measures of 
glycaemia and cardiovascular disease. Therefore, we examined the relationships of fasting glucose and glycated 
haemoglobin (HbA1c) with brachial and central blood pressure (BP), and measures of vascular structure and 
function after five years in black South Africans. 
Setting and subjects: Nine hundred and twenty-eight participants were included as part of the Prospective Urban 
Rural Epidemiological (PURE) study in the North West Province. 
Outcome measures: Fasting glucose, HbA1c and brachial BP at two time points were determined. Central BP, 
augmentation index (AI) and carotid intima-media thickness (CIMT) were taken at follow-up.
Results: Fasting glucose [4.78 (3.50, 6.30) vs. 5 mmol/l  (3.96, 6.42)]; HbA1c [5.6 (4.9, 6.3) vs. 5.9% (5.2, 6.9) and (37 vs. 
41 mmol/mol)]; and BP (134/88.1 vs. 138/89.5 mmHg) increased significantly over five years (p-value < 0.05). 
However, an association was absent between BP, AI or CIMT and either baseline or the five-year change in glucose 
or HbA1c. Multivariate analyses confirmed that neither glucose or HbA1c predicted changes in BP, CIMT or AI, 
but factors that did associate significantly were age, male gender, rural location, abdominal obesity, alcohol 
intake, total cholesterol to high-density lipoprotein ratio, C-reactive protein and antihypertensive medication 
(R2, ranging from 0.24-0.36).
Conclusion: Although both BP and measures of glycaemia increased significantly over five years in black South 
Africans, glucose was not independently associated with BP or measures of large artery structure or function. We 
suggest that fasting glucose and HbA1c below the threshold of diagnosing diabetes should not be used in isolation 
to predict cardiovascular risk in African individuals.
 Peer reviewed. (Submitted: 2013-04-12. Accepted: 2013-05-16.) © SEMDSA JEMDSA 2013;18(3):148-153
Introduction
Cardiovascular disease is a major cause of death in sub-
Saharan Africa. Hypertension and diabetes mellitus are 
the leading culprits.1 Hypertension is twice as common 
in patients with type 2 diabetes than it is in patients 
without it,2 which indicates a strong link between 
hypertension and chronically elevated glucose. 
Maruthur et al reported that black African American 
participants were more likely to have higher chronic 
glucose levels, as measured by glycated haemoglobin 
(HbA1c), than white participants.
3 This may indicate an 
elevated risk of cardiovascular disease.
Previously, the prevalence of type 2 diabetes in 
Africa was rare. The famous Dr Cook said: “Diabetes 
is very uncommon, but very fatal” in his notes 
on disease in Africa.4 However, recent evidence 
indicates an increasing incidence and prevalence of 
type 2 diabetes mellitus throughout Africa, which has 
accompanied rapid urbanisation.5-7 This implies severe 
consequences with regard to cardiovascular morbidity 
and mortality.
Although basic research has implicated an association 
between cardiovascular function and glucose, limited 
information is available on this association in longitudinal 
epidemiological studies on black South Africans. In an 
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attempt to address these issues, we aimed to confirm 
whether or not measures of glycaemia and blood 
pressure (BP) increased significantly over a five-year 
period in black South Africans. Secondly, we assessed 
whether or not baseline and the five-year change in 
glycaemic status (as measured by fasting glucose 
and HbA1c), were associated with BP, subclinical 
atherosclerosis and cardiovascular function.
Method
Study design
The Prospective Urban Rural Epidemiological (PURE) 
study is a multinational, longitudinal study, particularly 
pertaining to low- and middle-income countries, 
including South Africa.8,9 The data used in this study 
form part of the baseline data collected in the South 
African leg of the PURE study that was performed in 
North West province in which 1 004 rural, and 1 024 
urban participants, took part. Follow-up data collection 
took place in 2010, in which 1 279 subjects participated. 
Our specific substudy was embedded within the South 
African PURE study, and included 928 volunteers with 
baseline and follow-up data, who were older than 
32 years of age, from urban (Ikageng; Potchefstroom) 
and rural (Ganyesa, Moswana and Tlakgameng; 
Vryburg) environments, with no plans of moving in the 
future, and who were not pregnant or lactating. Subjects 
infected with the human immunodeficiency virus (HIV) 
(n = 212), and making use of diabetes medication (self-
reported) (n = 66) were excluded from this study. There 
was a good gender and locality distribution in the final 
group. Sixty-three per cent were women and 58% lived 
in rural, rather than urban settlements.
During recruitment, the protocol was explained in the 
subjects’ home language, and each participant was 
given an opportunity to ask questions. Afterwards, if 
an individual wanted to participate, written informed 
consent forms were obtained. Ethical approval for 
the study was obtained from the Ethics Committee of 
North-West University, which adheres to the principles 
of the 2008 Declaration of Helsinki. Subjects received 
pre- and post-counselling with regard to HIV testing. 
Data were treated confidentially, and laboratory and 
data analyses performed using anonymous numbers.
Organisational procedures
Participants were collected from their communities 
by the research team, and after a 10- to 15-minute 
drive, arrived at the research facility at approximately 
07h30. An introduction to the set-up, an explanation 
of the procedures and counselling on HIV were given, 
and the informed consent forms signed. Lifestyle 
and demographic data were obtained by trained 
fieldworkers using a standardised questionnaire in 
the participants’ language. Lifestyle data included 
tobacco use, alcohol intake, health history and 
medication use. 
Anthropometric measurements
Anthropometric measurements were obtained using 
the guidelines adopted from the National Institutes of 
Health-sponsored 1988 Arlie Conference. The subjects 
wore minimal or no clothing during the evaluation. 
Weight was measured to the nearest 0.1 kg. Weight 
was determined when the subjects were barefoot, 
using a portable digital Precision Health Scale® (A & 
D Company, Tokyo, Japan). Height was measured to 
the nearest millimetre in the upright standing position 
using an IP 1465® stadiometer (Invicta, London, UK). 
Waist circumference (WC) was measured over the 
abdomen between the costal margin and the iliac 
crest. Measurements were taken to the nearest 
millimetre, using a nonstretchable standard Holtain® 
tape (Apex Tool Group, Apex, USA). 
Cardiovascular measurements
Brachial BP was recorded using the validated Omron® 
HEM-757 (Omron Healthcare, Tokyo, Japan) automatic 
digital BP monitor on the right arm, after the subject 
had been in the sitting position for at least 10 minutes, 
at baseline and during follow-up data collection. Two 
measurements were taken with the right arm elevated 
to heart level, at five-minute intervals. Obtained 
cardiovascular variables included systolic blood 
pressure (SBP), diastolic blood pressure (DBP), pulse 
pressure (PP) and heart rate. Some cardiovascular 
measurements were only determined at follow-
up, including central SBP and augmentation index 
(AI), which were measured using the Omron® HEM-
9000AI (Omron Healthcare, Tokyo, Japan). Carotid 
intima-media thickness (CIMT) was obtained using a 
SonoSite® Micromaxx (SonoSite Inc, Washington, USA) 
and a 6- to 13-MHz linear array transducer. Images 
from at least two optimal angles of the left and right 
common carotid artery were obtained. Following 
previous prescribed protocols,10 these segments were 
imaged and measured. A single reader conducted 
measurements using a semi-automated programme, 
namely the Artery Measurement Systems® II v1.139 
(Chalmers University of Technology, Gothenburg, 
Sweden).
Blood sampling and biochemical analyses
A registered nurse collected blood from the brachial 
vein branches, using a sterile, winged infusion set and 
syringes, with minimal stasis before 12h00 to minimise 
the effects of diurnal variation. The subjects were asked 
to fast overnight (8-10 hours with no food or beverages, 
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excluding water). The blood was centrifuged for 
15 minutes (2 000 g at 4°C). Aliquots of plasma were 
frozen on dry ice, and stored in the field at -18°C for 
2-4 days, after which the samples were transported 
to a storage facility where they were kept at -82°C 
until analysis. Glycated HbA1c measurements were 
determined on-site on ethylenediaminetetraacetic acid 
(EDTA)-treated whole blood using the D-10 Hemoglobin 
Testing System® (#220-0101) from Bio-Rad Laboratories, 
Hercules, USA.  This system is based on the use of ion-
exchange, high-performance liquid chromatography 
to separate the different types of haemoglobin which 
are measured as they pass through a filtre photometer 
at 415 nm. The system was calibrated once a week 
using the D-10™ HbA1c Calibrator/Diluent set (#220-
0118), (Bio-Rad Laboratories) while Lypochek® Diabetes 
(# 740) control samples (Bio-Rad Laboratories) were run 
once a day. High-sensitivity C-reactive protein (CRP) 
was measured using a Synchron® LX System (Beckman 
Coulter Inc, Fullerton, USA) and the Cobas® Integra 
400 Plus System (Roche, Indianapolis, USA). Plasma 
glucose, gamma glutamyl transferase (GGT) and the 
lipid profile [total cholesterol (TC) and high-density 
lipoprotein (HDL) cholesterol] were measured using 
the Konelab® 20i (Thermo Scientific, 
Vantaa, Finland) and the Cobas 
Integra 400 Plus System instruments. 
HIV status was determined on the 
day of the data collection by a First 
Response Rapid HIV® card test (PMC 
Medical, Daman, India). In the event 
of a positive outcome, the result was 
confirmed with the Pareeshak® card 
test (BHAT, Bio-tech, India) at baseline, 
and with the Sensa® HIV 1/2 Test 
(Seyama Solutions, Johannesburg, 
South Africa) at year five.
Statistical analyses
Data were statistically analysed 
by means of Statistica® version 10 
(Statsoft Inc, Tulsa, USA). Variables 
that were not normally distributed 
were logarithmically transformed 
(fasting glucose, HbA1c, GGT 
and CRP). The five-year changes 
in continuous variables were 
determined using dependent t-tests. 
The McNemar test was employed for 
categorical variables. Multivariate 
forward stepwise regression analyses 
were used to assess the association 
between the different cardiovascular 
variables as dependant variables 
(either the five-year percentage change in SBP, DBP, 
and PP; or CIMT, central SBP and AI, which were only 
taken at follow-up). Independent variables included 
age, gender, rural or urban location, tobacco and 
antihypertensive medication use at baseline, baseline 
BP (either systolic, diastolic or PP as appropriate), 
baseline, and the percentage change in HbA1c, WC, 
TC to HDL ratio, GGT and CRP. Similar models were 
performed where baseline and the percentage 
change in HbA1c were replaced with baseline and the 
percentage change in fasting glucose levels as main 
independent variables.
Results
To address our first aim, we outlined the anthropometric, 
cardiovascular and biochemical characteristics of the 
study participants (n = 928) over the five-year follow-
up (Table I). As expected, brachial BP increased 
significantly, by approximately 4 mmHg for SBP, over 
five years. In addition, a significantly greater number 
of subjects were receiving antihypertensive therapy at 
the five-year follow-up. Fasting glucose also increased 
by an approximate 0.22 mmol/l, supporting an increase 
of 0.38% in HbA1c (p-value < 0.001). This significant 
Table I: Anthropometric, cardiovascular and biochemical characteristics of study 
participants over a five-year period (n = 928)
Characteristics 2005 2010 p-value
Age (years) 50.8 ± 9.88 55.4 ± 9.91 < 0.001
Anthropometric measurements
Weight (kg) 63.9 ± 17.3 65.4 ± 18.2 < 0.001
Body mass index (kg/m2) 25 ± 7.18 25.7 ± 7.53 < 0.001
Waist circumference (cm) 80 ± 12.8 81.9 ± 13.2 < 0.001
Cardiovascular measurements
Systolic blood pressure (mmHg) 134 ± 24.3 138 ± 24.1 < 0.001
Diastolic blood pressure (mmHg) 88.1 ± 14.5 89.5 ± 13.7 0.004
Pulse pressure (mmHg) 46.2 ± 15.1 48 ± 16.2 0.001
Central systolic blood pressure (mmHg) - 149 ± 24.5
Augmentation index (%)* - 92.7 ± 11.8
Carotid intima-media thickness (mm) 0.73 ± 0.15
Anti-hypertensive medication (%) 9.59 35.3 < 0.001
Smoking (%) 54.4 57.7 < 0.001
Biochemical measures
Fasting glucose (mmol/l) 4.78 (3.50-6.30) 5 (3.96-6.42) < 0.001
Glycated haemoglobin A1c  (%) 5.6 (4.9-6.3) 5.9 (5.2-6.9) < 0.001
Glycated haemoglobin A1c (mmol/mol) 37 (30-45) 41 (33-52) < 0.001
Total cholesterol to high-density 
lipoprotein ratio
1.04 ± 1.23 1.16 ± 2.36 0.16
Gamma glutamyl transferase (U/l) 55.5 (19.4-366) 45.1 (12.3-315) < 0.001
C-reactive protein (mg/l) 3.09 (0.25-39.8) 3.42 (0.29-31.9) 0.0062
Data are arithmetic mean ± standard deviation and geometric mean (95th percentile intervals) for logarithmically 
transformed variables. 
* Adjusted for heart rate
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increase in HbA1c was found, irrespective of gender 
and urban versus rural location (not shown).
We performed single linear regression analyses 
between cardiovascular measurements (ΔSBP, ΔDBP, 
ΔPP, central SBP, CIMT and AI) and baseline HbA1c, as 
well as the percentage change in HbA1c. Baseline HbA1c 
correlated significantly (r = 0.15, p-value < 0.001) with 
CIMT at follow-up, but we found no other significant 
correlation between any cardiovascular measurement 
and either baseline or the percentage change in HbA1c. 
We explored the association between HbA1c and CIMT 
further by dividing participants according to BP and 
HbA1c categories (< 5.7% and 5.7-6.4%) (Figure 1). There 
were no significant differences in CIMT between both 
HbA1c groups within optimal to prehypertensive BP 
categories (p-value > 0.23). Hypertensive individuals 
with HbA1c values ranging between 5.7% and 6.4% had 
significantly higher CIMT than participants with lower 
HbA1c levels (p-value 0.009).
In multivariate stepwise regression analyses (Tables 
II and III), with changes in brachial BP or follow-
up central SBP, CIMT or AI as dependent variables, 
the main independent variable, HbA1c, was not 
significantly associated with the dependent variables. 
Overall, age, gender, WC, the percentage change 
in WC and rural versus urban location were the most 
significant predictors of the various cardiovascular 
measurements (as dependant variables). We also 
repeated all six models in Tables II and III, and replaced 
HbA1c (baseline and percentage change) with fasting 
glucose (baseline and percentage change). All of 
the results were identical (not shown) as for HbA1c, 
i.e. without inclusion of glucose in the final models. The 
only exception was for the model with percentage 
PP as a dependent variable. In this model (R2 = 0.24), 
the percentage change in fasting glucose (β = -0.06, 
p-value 0.22) contributed to a variance in percentage 
change in PP.
Sensitivity analyses
We also made use of additional regression models 
to confirm the absence of an association between 
cardiovascular measures and HbA1c. Forward stepwise 
regression was carried out to assess the association 
between baseline HbA1c and baseline SBP, DBP and 
PP. We also performed forward stepwise regression 
analyses with similar models to those in Tables II and 
III, except these was performed separately in groups, 
namely urban, rural, men or women. HbA1c did not 
enter the model in any of these.
Discussion
Unsurprisingly, our study demonstrated significant 
increases in fasting glucose and HbA1c levels in black 
CIMT: carotid intima-media thickness, HbA1c: haemoglobin A1c
p-values refer to differences between carotid intima-media thickness categories of 
individuals with haemoglobin A1c ranging between 5.7% and 6.4% and individuals with 
lower haemoglobin A1c values within each blood pressure category
(Participants with haemoglobin A1c > 6.5% or 48 mmol/mol were excluded owing to 
the small sample size)
Figure 1: Carotid intima-media thickness according to baseline 


















































p = 0.45 p = 0.23
p = 0.66
p = 0.009
< 5.7 5.7 - 6.4 HbA1c (%)
Table II: Forward stepwise regression analyses with five-year percentage change in systolic blood pressure, diastolic blood pressure or 
pulse pressure as dependant variables (n = 928)





R2 = 0.26 R2 = 0.36 R2 = 0.24
Age (years) β 0.09 p-value 0.005 β -0.05 p-value 0.07 β 0.18 p-value 0.001
Gender (M, W) β -0.08 p-value 0.009 β -0.10 p-value 0.002
Rural, urban β -0.09 p-value 0.003 β -0.06 p-value 0.02 β -0.07 p-value 0.023
WC (cm) β 0.06 p-value 0.05 β 0.14 p-value < 0.001
ΔWC (%) β 0.07 p-value 0.02 β 0.09 p-value 0.001
SBP (mmHg) β -0.53 p-value < 0.001 - -
DBP ( mmHg) -  β -0.57 p-value < 0.001 -
PP (mmHg) - - β -0.51 p-value < 0.001
A-HP meds (no or yes) β 0.04 p-value 0.16
TC: HDL ratio β 0.05 p-value 0.071
ΔGGT (%) β 0.13 p-value < 0.001 β -0.06 p-value 0.041
A-HP meds: anti-hypertensive medication, β: beta, DPB: diastolic blood pressure, GGT: gamma glutamyl transferase, HDL: high-density lipoprotein, M: men, PP: pulse pressure, SBP: 
systolic blood pressure, TC: total cholesterol, W: women, WC: waist circumference 
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South Africans over a five-year period, independent of 
gender and rural or urban location. This increase was 
accompanied by significant increases in BP, thereby 
confirming previous observations.11,12 
Our most prominent finding was that despite the parallel 
elevations in both HbA1c and BP over five years, neither 
the baseline nor the five-year change in HbA1c was 
associated with an elevation in BP or PP. In addition, 
HbA1c was also not linked to measures of vascular 
structure and function (CIMT and AI) and central SBP 
that were taken at follow-up. In support of the findings 
on HbA1c, fasting glucose levels were also not linked to 
a change in BP or vascular structure and function.
These weak results are unexpected when viewed in 
the light of previous findings. More than a decade 
ago, Coutinho et al showed that there was a 
progressive relationship between glucose levels and 
cardiovascular risk below the threshold for diabetes 
in a meta-regression analysis of 95 783 men without 
diabetes.13 However, another carefully designed study 
by Temelkova-Kurktschiev et al suggested that a weak 
association existed between fasting plasma glucose 
and CIMT in individuals without diabetes.14 The Diabetes 
Epidemiology: Collaborative analysis Of Diagnostic 
criteria in Europe (DECODE) study group included 22 
cohorts in Europe, and concluded that the relationship 
between mortality and glucose was a J-shaped curve, 
rather than one that showed a threshold effect at 
high glucose levels. However, the relation between 
cardiovascular disease mortality and two-hour plasma 
glucose was graded and kept on increasing.15 
With much less evidence available for HbA1c as a 
measure of glycaemic status, it is assumed that the 
progressive relationship and J-shaped curve that were 
found between plasma glucose and cardiovascular 
disease risk and mortality13,15 is also applicable to HbA1c 
and cardiovascular disease risk. However, in a large 
prospective study, Pradhan et al found that although 
HbA1c predicted diabetes in normoglycaemic women, 
its association with incident cardiovascular events 
was low, and was largely attributable to coexistent 
risk factors.16 Our multiple regression results seem to 
support their findings, where other risk factors, such as 
age, male gender, rural location, abdominal obesity, 
excessive alcohol use, dyslipidaemia and inflammation 
all contributed significantly to the five-year change in 
BP, as well as CIMT and AI. However, when we explored 
CIMT according to BP and HbA1c categories in Africans 
without diabetes, the synergistic effects of hypertension 
and HbA1c contributed to a significant elevation in CIMT 
(Figure 1), which was not seen in prehypertensives, 
or those with lower BP or HbA1c. This supports recent 
findings by Paynter et al that cardiovascular risk 
prediction in patients with diabetes was improved by 
incorporating HbA1c in prediction models.
17 
The addition of a measure of glucose to improve 
prediction models is expected because of the well-
known effects of glucose on a mechanistic level. 
Hyperglycaemia inhibits major antioxidant systems (the 
interacting glutathione and thioredoxin system),18 that 
leads to an increased production of free radicals,19,20 
and also results in impaired endothelium-dependent 
Table III: Forward stepwise regression analyses with central systolic blood pressure, carotid intima-media thickness, or augmentation index 
as dependent variables (n = 928)
Characteristics Central SBP CIMT (mm) Augmentation index (%)
R2 = 0.31 R2 = 0.31 R2 = 0.16
Age (years) β 0.12 p-value < 0.001 β 0.43 p-value < 0.001 β 0.06 p-value 0.053
Gender (M, W) β -0.17 p-value < 0.001 β 0.32 p-value < 0.001
Rural, urban β -0.13 p-value < 0.001
WC (cm) β 0.12 p-value < 0.001 β -0.28 p-value < 0.001
ΔWC (%) β 0.05 p-value 0.122 β 0.05 p-value 0.087 β -0.05 p-value 0.114
SBP (mmHg) β 0.51 p-value < 0.001 β 0.14 p-value < 0.001
A-HP meds (no or yes) β 0.09 p-value 0.010
Smoke (no or yes) β 0.11 p-value 0.001
TC: HDL ratio β 0.07 p-value 0.028
ΔTC: HDL ratio β -0.04 p-value 0.160
GGT (log U/l) β -0.06 p-value 0.040 β 0.10 p-value 0.005
ΔGGT (%) β 0.05 p-value 0.118
CRP (log mg/l) β 0.07 p-value 0.032
ΔCRP (%) β -0.04 p-value 0.162
A-HP meds: anti-hypertensive medication, β: beta, CIMT: carotid intima-media thickness, CRP: C-reactive protein, GGT: gamma glutamyl transferase, HDL: high-density lipoprotein, M: 
men, SBP: systolic blood pressure, TC: total cholesterol, W: women, WC: waist circumference
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vasodilation of the micro- and macrocirculation 
through inhibition of endothelial nitric oxide synthase 
activity.21-24 Therefore, glucose may causally relate 
to vascular dysfunction and atherosclerosis through 
various mechanisms that are evident in the literature. 
Nevertheless, in our study, we did not find an 
independent relationship between HbA1c and BP or 
CIMT over five years. The reason for this absent link is 
unclear, but we expect that chronic hyperglycaemia 
exerts certain effects on the vasculature that may only 
be observed over a longer follow-up period. 
Our results suggest that the effects of hyperglycaemia 
on vascular deterioration take longer in Africans, but 
this needs to be confirmed in future studies. This result 
is especially surprising because of the known link 
between hyperinsulinaemia and salt sensitivity which 
has been demonstrated in black populations.25,26 In 
our study, we did not measure salt sensitivity or insulin 
levels. Therefore, future studies should include these 
measures to identify the causal pathways that underlie 
the development of both diabetes and cardiovascular 
disease in black South Africans.
This study should be viewed within the context of its 
strengths and limitations. The strengths include the 
longitudinal study design which included HbA1c and 
advanced cardiovascular measures in a large sample 
of 928 African individuals. Weaknesses are that several 
measurements (central SBP, CIMT and AI) were not 
taken at baseline, and that a longer follow-up period 
may have been required. Glycaemia was not assessed 
with an oral glucose tolerance test which might have 
assisted in better understanding the level of glycaemia 
in our population. Our sample was also selected from 
specific areas where unemployment is common. The 
applicability of our results to groups with a higher socio-
economic class should be confirmed.
Conclusion
Despite parallel elevations of fasting glucose, HbA1c 
and BP over five years in a sample of 928 Africans, 
no independent association between either baseline 
or the five-year change in glycaemic status and BP 
and CIMT were found. Our results suggest that fasting 
glucose and HbA1c below the threshold for diagnosing 
diabetes should not be used in isolation to predict 
cardiovascular risk in African individuals. 
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